Eolo Pharma key facts
as of Oct 2026- Developer of a pharmacological platform designed to treat obesity and its related chronic diseases through targeted small-molecule therapies.
- Eolo Pharma is valued at approximately $18.0M as of Oct 2026 (last reported valuation).
- It has raised $7.7M; the latest was Later Stage VC ($170K) in Mar 2025.
- Notable investors include Cites Startups, Ficus Capital, Securitas Biosciences Group.
- Status: Privately Held (backing).
Eolo Pharma's last reported valuation, Sep 2022. Nothing priced has surfaced since.
- ·Watch Eolo Pharma: the Monday email on marks, rounds and moves
Eolo Pharma funding rounds
No funding rounds for Eolo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Eolo Pharma
3Eolo Pharma valuation
Eolo Pharma's last reported valuation was $18 million in Sep 2022. No priced round, secondary trade or fund mark has surfaced since.
Eolo Pharma investors
3 investors are on record for Eolo Pharma, including Cites Startups, Ficus Capital and Securitas Biosciences Group.
About Eolo Pharma
Developer of a pharmacological platform designed to treat obesity and its related chronic diseases through targeted small-molecule therapies. The company offers a unique library of novel chemical entities, including thermogenic compounds like MVD1 that address metabolic and neuroinflammatory conditions, enabling healthcare providers to manage obesity, type 2 diabetes, and neurodegenerative disorders with more precise and effective treatments.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2017
- Employees
- 8
- Website
- eolo-pharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.